COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review

Udo Bonnet, MD1,2 and Georg Juckel, MD3

Abstract:

**Purpose/Background:** Studies for repurposed drugs in severe acute respiratory syndrome coronavirus type 2–infected and coronavirus disease 2019 (COVID-19) patients are ongoing. According to preclinical research, antidepressants (ADs) might be useful in the treatment of COVID-19.

**Methods/Procedures:** We conducted a scoping review including clinical studies on AD effects on SARS-CoV-2 infection and COVID-19.

**Finding/Results:** As of January 2, 2022, we found 14 clinical studies, which could be included into this review. Among them, there were 2 randomized, placebo-controlled studies and 2 prospective parallel-group studies about the efficacy/effectiveness and tolerability of fluvoxamine. The remaining studies were mainly retrospective studies considering COVID-19 hospital populations predominantly exposed to fluoxetine (N = 3), other selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors (SNRI), and trazodone. The vast majority were hospital studies and assessed COVID-19 severity (morbidity) and mortality as primary endpoints. The only outpatient study (fluvoxamine) investigated the COVID-19–related hospitalization rate, and 1 psychiatric hospital study (SSRI, SNRI, trazodone) focused on the SARS-CoV-2 infection rate.

**Implications/Conclusions:** At present, the best evidence of an “anti–COVID-19” potential of ADs exists for fluvoxamine and, to a lesser extent, for fluoxetine. Preliminary evidence had found that patients exposed to SSRIs or SNRIs substance classes might have had a reduced mortality risk and that trazodone might reduce SARS-CoV-2 infection rate. Three studies found no relevant influence of ADs on COVID-19 morbidity and mortality, and 1 study described increased mortality. The latter study, however, did not differentiate between psychotropic medication and ADs. Tricyclics and monoamine oxidase inhibitors are still absolute not differentiate between psychotropic medication and ADs. Trazodone might reduce SARS-CoV-2 infection rates. Three studies (SSRI, SNRI, trazodone) focused on the SARS-CoV-2 infection rate.

**Key Words:** SARS-CoV-2, clinical studies, antidepressants, COVID-19 morbidity

From the 1Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Evangelisches Krankenhaus Castrop-Rauxel, 2Department of Psychiatry and Psychotherapy, LVR-Hospital Essen, Faculty of Medicine, University of Duisburg-Essen, Essen; and 3Department of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum, Germany. Received December 3, 2021; accepted after revision January 22, 2022. Address correspondence to: Udo Bonnet, MD, Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Evangelisches Krankenhaus Castrop-Rauxel, Grutzhohalzelle 21, D-44577 Castrop-Rauxel, Germany (e-mail: udo.bonnet@uni-due.de). Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0271-0749 DOI: 10.1097/JCP.0000000000001543

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
| Authors | Country | Population/Sample Size/Context | Study Design | Main Outcome According to ADs | Limitations* | EBM Level† and AD-Related Message |
|---------|---------|--------------------------------|--------------|-------------------------------|--------------|----------------------------------|
| Reis et al, 2022 | Brazil/Canada | High-risk symptomatic Brazilian adults with SARS-CoV-2 (n = 1497; median age, 50 y; 58% females); between June 2, 2020, and September 9, 2021; second and third waves of the pandemic | Multicenter, adaptive platform RCT; 100 mg fluvoxamine bid vs placebo for 10 d | Serious COVID-19–related emergencies (RR, 0.68; 95% BCI, 0.52–0.88) and deaths (OR, 0.68; 95% CI, 0.36–1.27) were less likely and less frequent in the fluvoxamine group than in the placebo group; both in a clinically relevant fashion. | Confounding variables, such as previous and concomitant medications, were not sufficiently controlled; short duration | EBM level 2 Fluvoxamine treatment predicted significantly lower COVID-19–related mortality and fewer emergencies than placebo condition |
| Lenze et al, 2020 | United States | Adult outpatients with severe acute respiratory COVID-19, with symptom onset within 7 d and oxygen saturation of 92% or greater (n = 152); between April 10, 2020, and August 5, 2020, first wave | Single-center, double-blind, randomized, fully remote (contactless) clinical trial of patients treated with fluvoxamine (100 mg tid, n = 80, mean age: 46 y, 70% females) vs placebo (n = 72, mean age: 45, 74% females) over 15 d | Significantly fewer clinical deteriorations in the fluvoxamine group (0 of 80 patients) vs the placebo group (6 of 72 patients); absolute difference, 8.7% (95% CI, 1.8%–16.4%) from survival analysis; log-rank, \( P = 0.009 \). More serious events in the placebo group (6 vs 1). Fewer serious (1) and other (11) adverse events in the fluvoxamine than in the placebo group (6 and 12) | Small homogeneous sample, short follow-up duration, vague outcome measures, 20% attrition rate | EBM level 2 Significantly more favorable COVID-19 outcomes among the fluvoxamine-treated patients than in the placebo group |
| Vai et al, 2021 | Italy | Patients with psychiatric disorders plus COVID-19 (n = 43,938) compared with controls without psychiatric disorders, plus COVID-19 (n = 1,425,793); between January 1, 2020, and March 5, 2021, first and second waves | Epidemiologic systematic review and meta-analysis of COVID-19 outcomes (33 and 23 nonrandomized studies were included, respectively, mainly retrospective cohort studies with EBM level 3 from United States, Israel, South Korea, Brazil, and Western Europe) | COVID-19 mortality was related to prescription of antipsychotics (OR, 3.71 [95% CI, 1.74–7.91]; \( F^2 = 90.31\% \)), anxiolytics (OR, 2.58 [1.22–5.44]; \( F^2 = 96.42\% \)), and ADs (OR, 2.23 [1.06–4.71]; \( F^2 = 95.45\% \)). For psychotic disorders, mood disorders, antipsychotics, and anxiolytics, the relationship remained significant after adjustment for age, sex, and other confounders—but no longer for ADs. Psychiatric disorders were associated with increased risk of hospitalization (OR, 2.24 [1.70–2.94]; \( F^2 = 88.80\% \)). | Only 9 of the 23 studies included into the meta-analysis considered comorbid somatic conditions, suggesting a considerable underestimation of these conditions. Most of the included evidence relied on electronic medical records that did not allow a precise analysis of clinical variables, eg, separation between unipolar and bipolar mood disorders. Some studies had low quality or examined small samples of patients with psychiatric disorders. | EBM level 2 In COVID patients with severe mental illness, AD-prescription was not related to COVID-19 mortality |

Continued next page
| Authors and Country | Population/Sample Size/ Context | Study Design | Main Outcome According to ADs | Limitations* | EBM Level† and AD-Related Message |
|---------------------|--------------------------------|--------------|--------------------------------|--------------|----------------------------------|
| **Prospective studies** | | | | | |
| Seftel and Boulware, 2021 | SARS-CoV-2–infected adult outpatients (n = 113; mean age, 42 y; 25% females); between November 2020 and December 2020, first wave | Pragmatic prospective parallel group study, fluvoxamine (n = 64) vs observational group not exposed to fluvoxamine (n = 48); fluvoxamine was prescribed with a 50- to 100-mg loading dose and then 50 mg bid for 14 d | Hospitalization rate was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone (P = 0.05). At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation (P < 0.001). No serious adverse event, no premature discontinuation due to an adverse event | Small sample size; no randomization; confounding variables, such as concomitant medications and comorbidity, were not sufficiently considered; short duration | EBM level 3 Fluvoxamine treatment predicted fewer hospitalizations and residual symptoms of SARS-CoV-2–infected patients |
| Calusic et al, 2021 | Adult patients with COVID-19 (n = 102, age stratified, 58% females) admitted to an ICU; between March 2021 and April 2021, second wave | Pragmatic prospective parallel group study; fluvoxamine (100 mg tid) was added to standard therapy of COVID-19 patients admitted to an ICU (n = 41) and was compared with a matched (for age, sex, vaccination) control group of ICU patients with COVID-19 (n = 41); observation period, 15 d; thereafter 7 d fluvoxamine taper | General mortality was significantly lower in the fluvoxamine group (58.8%) than in the control group (76.5%); HR, 0.58; 95% CI (0.36–0.94). In men, no statistically significant differences were found between the groups. In men, coronary artery disease was significantly more frequent than in females. In the fluvoxamine group, CRRT was significantly more frequent. Fluvoxamine was well tolerated; there were no statistically significant differences of adverse effects between the groups with the exception of CRRT. | | EBM level 3 Fluvoxamine treatment significantly predicted lower COVID mortality in females |
| **Retrospective studies** | | | | | |
| Oskotsky et al, 2021 | Adult patients with COVID-19 (n = 90,834), data from the Cerner Real World COVID-19 Database (comprising records of patients diagnosed with COVID-19 or COVID-19 exposure who had an emergency department or urgent care visit or were admitted for observation or hospitalized); between January 2020 and September 2020, first wave | Retrospective observational clinical register study (n = 3401 exposed to SSRI vs n = 80,183 not exposed to SSRI, cp) | In comparison with matched cp, the RR of mortality was reduced among patients prescribed any SSRI (41.6% vs cp 16.6%, adj P = 0.03); prescribed fluoxetine (9.8% vs cp 13.3%, adj P = 0.03); prescribed fluoxetine or fluvoxamine (10% vs cp 13.3%, adj P = 0.03); prescribed SSRI that is not fluoxetine or fluvoxamine (15.4% vs cp 17%, adj P = 0.06) | Retrospective design, considerable data heterogeneity, no documentation whether the patients had indeed used their prescription medications, dose uncertainty | EBM level 3 SSRI prescriptions significantly predicted lower COVID-19 mortality, especially the fluoxetine and fluvoxamine prescriptions |
| Study | Setting | Design | Sample Description | Outcome Measures | Results | Limitations |
|-------|---------|--------|--------------------|------------------|---------|-------------|
| Barcella et al, 2021 | Denmark | Cross-sectional | 16- to 80-year-old patients with COVID-19 (n = 144,321) | Average risk ratio for poor COVID-19 outcome and death was significantly increased for patients with severe mental illness including schizophrenia spectrum disorders (2.43 [95% CI, 1.79–3.07]), bipolar disorder (2.11 [95% CI, 1.25–2.97]), and unipolar depression (1.70 [95% CI, 1.38–2.02]) and for patients who redeemed psychotropic drugs (1.70 [95% CI, 1.48–1.92]). Psychotropic drugs included antipsychotics, lithium, ADs, and psychostimulants. The number of psychotropic drugs was not significantly associated with a higher risk of death and severe COVID-19. | Considerable data heterogeneity and low specificity. For instance, the increased risk of unfavorable COVID-19 outcomes could result from a delayed diagnosis of COVID-19 owing to treatment nonadherence, which is high among patients with severe psychiatric diseases. | EBM level 3 |
| Hoertle et al, 2021 | France | Retrospective multicenter | Adult patients at Great Paris University hospitals hospitalized for COVID-19 (n = 7230); of these, n = 345 patients (4.8%) were exposed to an AD at admission. Chart records from the L'AP-HP clinical Data Warehouse initiative (containing various data of all inpatient visits for COVID-19 to any of the 39 AP-HP Greater Paris University hospitals) | Significant association between AD use and reduced risk of intubation or death (HR, 0.56; 95% CI, 0.43–0.73; P < 0.001). Exploratory analysis: this association was significant for both SSRI (fluoxetine, paroxetine, escitalopram) and non-SSRI (venlafaxine, mirtazapine). The association between AD use and the endpoint was only observed for patients receiving an AD during the visit and not in those who received it only within the 3 mo before hospital admission. | AD use significantly predicted fewer intubations and mortality rates than non-AD use | EBM level 3 |

Continued next page
### Table 1. (Continued)

| Authors Country        | Population/Sample Size/ Context | Study Design                      | Main Outcome According to ADs                                                                 | Limitations*                                                                 | EBM Level and AD-Related Message                                                                 |
|------------------------|---------------------------------|-----------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Hoertel et al, 2021¹⁹  | France                          | Adult patients at Great Paris University hospitals hospitalized for COVID-19 (n = 2846, 37.4% females); of these, 277 (9.4%) were exposed to FIASMA medications at admission; AP-P database | Retrospective multicenter clinical register study, primary endpoint was the time from study baseline to intubation or death, observational period from January 24, 2020, to May 1, 2020, first wave | Significant association between FIASMA medication use and reduced risk of intubation or death. The following ADs were included into the FIASMA medication comprising, eg, additional organic calcium antagonists and neuroleptics: amitriptyline, n = 8; clomipramine, n = 1; paroxetine, n = 16; escitalopram, n = 12; sertraline, n = 7; and duloxetine; n = 5. FIASMA AD medication is associated with significantly lower risk of intubation and death compared with the non-FIASMA medication paracetamol (HR, 0.60 [95% CI, 0.45–0.79]; P < 0.001). No FIASMA medication vs FIASMA medication with low or no affinity to SIR-1s (HR, 0.46 [95% CI, 0.32–0.68]; P < 0.001). | Retrospective design; no adjustment for multiple testing; incomplete information about the indication for AD prescriptions, its duration, and adherence as well as the period of COVID-19 predmission; dose un certainty; underestimation of tricyclics (only 9 of 49 charts) | EBM level 3 FIASMA medication use (including ADs, neuroleptics, amiodipine) significantly predicted fewer intubations and mortality rates than non-FIASMA medication use — the same applied to the two subgroups of chart records of patients exposed especially to FIASMA ADs or, more specifically, to low/no SIR-1 receptor FIASMA ADs |
| Diez-Quevedo et al, 2021¹⁰ Spain | Adult patients (mean age, 61.3 y; 42.9% females) with COVID-19 (n = 2150), admitted to a tertiary university hospital in Barcelona between January 3, 2020, and November 17, 2020, first wave | Retrospective observational chart record study; 1011 patients (47%) received psychotropic medications: 36% benzodiazepines, 22% ADs, and 21% antipsychotics | Patients with previous year's benzodiazepine and AD treatments (mostly mirtazapine and SSRIs) were independently associated with lower mortality risk (hazard ratios: benzodiazepines, 0.47 [95% CI, 0.29–0.78], P = 0.003; and ADs, 0.43 [95% CI, 0.25–0.74], P = 0.002). Antipsychotic treatment history (mostly quetiapine and haloperidol) was not associated with mortality. | Retrospective design, considerable data heterogeneity, no documentation whether the patients had indeed used their prescriptions, dose uncertainty | EBM level 3 AD treatment significantly predicted lower mortality risk |
| Clelland et al, 2021¹⁷ United States | Adult patients (n = 165, age and sex stratified) admitted to The Rockland Psychiatric Center, Orangeburg, New York; between June 2, 2020, and July 31, 2020; first wave | Retrospective cohort study of psychiatric in-patients investigating whether ADs can modify the risk of SARS-CoV-2 infection; n = 91 SARS-CoV-2–positive vs n = 74 SARS-CoV-2–negative patients | Patients receiving ADs (SSRI, SNRI, trazodone) experienced significantly fewer COVID-19 infections (fully adj OR, 0.28 [95% CI, 0.09–0.83]; P = 0.023). Exploratory analyses of individual AD use found a significant association between lower infection risk and fluoxetine (P = 0.023), as well as trazodone (P = 0.001) intake. There was small but significant association of chlorpromazine equivalent daily dose with COVID-19 infection rate. | Retrospective design, small sample size, no documentation of severity outcomes following COVID-19 infection, dose uncertainty | EBM level 3 Fluoxetine and trazodone significantly predicted lower SARS-CoV-2 infection rates |
| Study | Country | Study Design | Participants | Findings |
|-------|---------|--------------|--------------|----------|
| Bonnet et al, 2022 | Germany | Retrospective longitudinal, multicenter psychiatric inpatient study | SARS-CoV-2–infected adult psychiatric inpatients (eligible, n = 107; included, n = 96; mean age, 61.5 y; 54% females); between November 2020 and March 2021, second wave | ADs (without fluvoxamine and fluoxetine) did not predict COVID-19 duration but significantly negatively predicted respiratory symptom-load (95% CI). The significant relationship disappeared after adjustment for multiple testing. |
| Németh et al, 2021 | Hungary | Retrospective case-control study | Adult patients (mean age, 66 y; 45.4% females) with COVID-19–related pneumonia (n = 269), admitted to the Uzsoki Teaching Hospital of the Semmelweis University in Budapest, between March 17, 2021, and April 22, 2021, third wave | None of the tested medications (AD, neuroleptics, anticonvulsants, benzodiazepines, antihypertensive agents, PPIs, anticoagulants, statins, RAAS inhibitors) was associated with the duration of COVID-19 (primary outcome). According to 95% CIs of regression coefficients, respiratory and neuropsychiatric symptom load was significantly and negatively related to prescription of ADs and anticoagulants, respectively. Fatigue was negatively and positively related to RAAS inhibitors and PPIs, respectively. These significant relationships disappeared with P value adjustment owed to multiple testing. The mean total psychiatric burden was not influenced across the study. |
| Fei et al, 2021 | Italy | Retrospective case-control study | Adult patients (mean age, 70 y; 40.3% females) with COVID-19–related pneumonia (n = 402), admitted to Internal Medicine wards of the Florence University; first wave | None of the tested medications (AD, neuroleptics, anticonvulsants, benzodiazepines, antihypertensive agents, PPIs, anticoagulants, statins, RAAS inhibitors) was associated with the duration of COVID-19 (primary outcome). According to 95% CIs of regression coefficients, respiratory and neuropsychiatric symptom load was significantly and negatively related to prescription of ADs and anticoagulants, respectively. Fatigue was negatively and positively related to RAAS inhibitors and PPIs, respectively. These significant relationships disappeared with P value adjustment owed to multiple testing. The mean total psychiatric burden was not influenced across the study. |

| Study | Country | Study Design | Participants | Findings |
|-------|---------|--------------|--------------|----------|
| Retrospective design, small sample size, recall errors of the interviewed physicians, no control group with nonpsychiatric patients, loss of follow-up rate of 11.3% (not included were 11 patients who wanted to be directly discharged after diagnosis with SARS-CoV-2 infection — all symptom free at that time) | Germany | Retrospective case-control study | Patients receiving fluoxetine therapy were 0.33 times (95% CI 0.16–0.68) less likely to die than those who had not received fluoxetine within 2 to 28 d. This effect was independent on concomitant antiviral therapy. There were 3 adverse events (severe hyponatremia, increase of transaminases, and confusion), which led to fluoxetine treatment stop in each case. | EBM level 3 |
| Retrospective design, no documentation whether the patients had indeed used their prescriptions, dose uncertainty, significant intergroup differences (fluoxetine group received significantly more frequent antiviral therapy) | Hungary | Retrospective case-control study | Mortality rate: no significant difference between the groups; ARDS (P < 0.02) and endotracheal intubation (0.04) significantly lower in the AD-treated group; ADs: SSRI and SNRI | EBM level 4 |
| Retrospective design, small sample size, recall errors of the interviewed physicians, no control group with nonpsychiatric patients, loss of follow-up rate of 11.3% (not included were 11 patients who wanted to be directly discharged after diagnosis with SARS-CoV-2 infection — all symptom free at that time) | Italy | Retrospective case-control study | Mortality rate: no significant difference between the groups; ARDS (P < 0.02) and endotracheal intubation (0.04) significantly lower in the AD-treated group; ADs: SSRI and SNRI | EBM level 4 |

Clinical trials and observational studies are sorted by EBM level and sample size.

*Drugs of abuse (eg, alcohol cannabis, opioids, cocaine, amphetamines) were not sufficiently considered, although these recreational drugs can modulate key components of the immune response machinery.*

†According to the Oxford Centre for Evidence-Based Medicine Levels of Evidence Working Group (Jeremy Howick, Iain Chalmers [James Lind Library], Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton, Olive Goddard, and Mary Hodgkinson). “The Oxford Levels of Evidence 2.” The Levels of Evidence, version 2.1. Available at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/cebm-levels-of-evidence. Accessed February 22, 2022.

‡Definition of FIASMA medication.
with SARS-CoV-2. Exclusion criteria comprised all animal, non-clinical, and nonepidemiological studies.

RESULTS/FINDINGS
We could include 14 studies (Fig. 1), which were summarized in Table 1. In short, 2 placebo-controlled randomized studies,12,13 both EBM level 2, demonstrated a beneficial role of fluvoxamine (100 mg twice a day or 3 times a day over 14 days) as add-on in the treatment of COVID-19: in these studies,12,13 fluvoxamine significantly reduced serious COVID-19 outcomes. This and the good tolerability and safety of fluvoxamine were supported by a small pragmatic prospective Croatian study (EBM level 3).14 Another small pragmatic prospective study tested a fluvoxamine loading dose protocol (50 to 100 mg, followed by 50 mg twice a day) alongside 14 days in SARS-CoV-2–positive adult outpatients, who were not necessarily affected by COVID-19. In this 14-day study, fluvoxamine treatment predicted fewer hospitalizations and residual symptoms of SARS-CoV-2–infected patients (EBM level 3).15 The second best evidence of an “anti-COVID” potential of ADs exists for fluoxetine; at present, it is shown only in retrospective studies: 1 larger study (EBM level 3)16 and the other 2 with smaller sample sizes (EBM level 317; EBM level 4).18 The smallest study in this context (EBM level 4)18 tested an add-on treatment of 20 mg fluoxetine up to 28 days in patients receiving an antiviral treatment of COVID-19 pneumonia, whereas the other 2 studies16,17 had dose uncertainties. Other selective serotonin reuptake inhibitors (SSRI), mirtazapine, venlafaxine, and trazodone were associated with reduced SARS-CoV-2 infection rates as well as reduced COVID-19 morbidity and mortality in 4 retrospective studies, 1 with psychiatric inpatients (EBM level 3)17 and the other 3 evaluating larger general hospital samples affected by COVID-19, all EBM level 37,9,19 Three further retrospective studies described no relevant influence of ADs on COVID-19 severity and mortality, 2 of them using small sample sizes (EBM level 320 and EBM level 4),21 and the remaining study with a large heterogeneous COVID-19 population (EBM level 2).4 The least specific study was cross-sectional and described that psychotropic drugs (including ADs) were associated with increased COVID-19 severity and mortality in the Danish general population (EBM level 3).1

DISCUSSION
At present, especially fluvoxamine (100 mg twice a day or 3 times a day) seems to exert protective effects on COVID-19 morbidity and mortality (supported by 2 randomized placebo-controlled clinical trials [both EBM level 2, Table 1]12,13 and 1 pragmatic prospective study [EBM level 3, Table 1]).14 The only outpatient study included into this review used lower fluvoxamine doses (50 mg twice a day) in an outpatient everyday setting and found significantly reduced COVID-19–related hospitalization (EBM level 3, Table 1).15

In this context, it should be outlined that fluvoxamine, like other ADs, is no “panacea,” given its special pharmacokinetics as a powerful inhibitor of the CYP11A2 and CYP2C19 systems as well as an average inhibitor of CYP3A4, all together catabolic pathways with a relevant genetic variability in the general population.22 Against this background, problematic drug-drug interactions have been reported with fluvoxamine, such as considerable increases of the blood levels of, for example, diazepam, bromazepam, alprazolam, clozapine, tricyclics, mirtazapine, and many other somatic medications as well as adverse effects during cross-over titration from fluvoxamine (itself mainly metabolized by CYP2D6 and CYP1A2) to other serotonergic drugs.22,23 Citing the last Cochrane analysis, fluvoxamine was neither superior nor inferior to any other ADs in terms of efficacy and tolerability in the acute phase treatment of depression;24 especially nausea/vomiting was more frequently reported with fluvoxamine than with tricyclics.24 According to the studies elaborated here, fluvoxamine was well tolerated by COVID-19 patients (Table 1). More data are necessary about dosing, treatment timing and duration, tolerability/safety in various populations, and effectiveness/efficacy against post/long COVID and different SARS-CoV-2 variants. We read that 4 larger trials are underway in United States and Canada.25

FIGURE 1. Flow chart of the search strategy used during the scoping review of epidemiological and clinical studies about influence of ADs on SARS-CoV-2 infection and COVID-19 outcomes.
Known Fluvoxamine and Fluoxetine Anti–COVID-19 Mechanisms

The idea to test the anti–COVID-19 potential of fluvoxamine, an old and inexpensive SSRI, however less frequently prescribed in these days, was based upon preclinical research, where fluvoxamine was shown to augment a cellular key anti-inflammatory system by stimulating the sigma-1 receptor (SIR-1), an endoplasmic reticulum (ER) chaperone membrane protein involved, for example, in the control of the ER stress response. For instance, SIR-1 was identified as an essential inhibitor of cytokine production in a murine model of septic shock.26 Another SSRI, that is, fluoxetine, was demonstrated to inhibit SARS-CoV-2 entry into epithelial cells as well as SARS-CoV-2 replication.27-28 Because fluoxetine and fluvoxamine share a potent SIR-1 agonism, it is possible that both SSRIs can prevent severe COVID-19 by abating hyperinflammatory events, such as the cytokine storm after ER stress due to SARS-CoV-2 replication.29,30 Moreover, decreased immunoglobulin E-mediated mast-cell degranulation and interference with endosomal viral trafficking were discussed as mechanisms to limit this hyperinflammatory immune response.31,32 A recent large retrospective clinical register study corroborated that both fluvoxamine and fluoxetine prescriptions negatively predicted COVID-19 mortality (EBM level 3, Table 1).19 Moreover, an anti–COVID-19 potential of fluoxetine was supported by 2 further, although smaller, retrospective studies.17,18

Further Broader Possible Anti–COVID-19 Mechanisms of ADs

The SIR-1 agonist effect as a central explanation of the effect of fluvoxamine remains to date uncertain in the absence of any preclinical or clinical data specific to COVID-19 supporting this effect and seems unable to explain associations observed between non-SIR-1 or very-low SIR-1 ADs (such as paroxetine, mirtazapine, and venlafaxine) and reduced risk of intubation or death (Table 1) as well as anti-inflammatory effects observed with a broad range of ADs (and not only the SIR-1 ADs fluvoxamine and fluoxetine) in individuals with major depression.8 Contrariwise, several preclinical (in vitro and ex vivo) and observational studies suggest that inhibition of acid sphingomyelinase (ASM)/ceramide system plays a potentially important role and may explain both potential antiviral and anti-inflammatory effects of certain ADs in COVID-19.19,23,28 Particularly, among SSRIs, the magnitude of the in vitro inhibition of ASM, which varies across molecules (eg, fluoxetine > paroxetine > fluvoxamine > other SSRIs),43,35 appears to correlate with the magnitude of the in vitro antiviral effect against SARS-CoV-2.28,36

In this context, most ADs belong to a large group of special lipophilic, lysosomotropic, amine, and weak bases (comprising also many tricyclic ADs, some antipsychotics like chlorpromazine, and cell-surface ASM.33) and many tricyclic ADs, some antipsychotics like chlorpromazine are also lipophilic, lysosomotropic, amine, and weak bases (comprising also many tricyclic ADs, some antipsychotics like chlorpromazine, and cell-surface ASM.33) and can prevent severe COVID-19 by abating hyperinflammatory events, such as the cytokine storm after ER stress due to SARS-CoV-2 replication.29,30 Moreover, decreased immunoglobulin E-mediated mast-cell degranulation and interference with endosomal viral trafficking were discussed as mechanisms to limit this hyperinflammatory immune response.31,32 A recent large retrospective clinical register study corroborated that both fluvoxamine and fluoxetine prescriptions negatively predicted COVID-19 mortality (EBM level 3, Table 1).19 Moreover, an anti–COVID-19 potential of fluoxetine was supported by 2 further, although smaller, retrospective studies.17,18

CONCLUSIONS

At present, the best evidence of an anti–COVID-19 potential of ADs exists for fluvoxamine and, to a lesser extent, for fluoxetine. Preliminary evidence was found for other SSRI, selective norepinephrine reuptake inhibitors, and trazodone exposures. Tricyclics and MAO inhibitors are still “dark zones” in COVID-19 research. Further well-controlled studies testing the effectiveness/efficacy and tolerability/safety (and treatment timing/duration) of different AD substance classes in COVID-19 patients of various populations are warranted.

AUTHOR DISCLOSURE INFORMATION
The authors declare no conflicts of interest.

REFERENCES
1. Barcella CA, Polecwiatrek C, Mohr GH, et al. Severe mental illness is associated with increased mortality and severe course of COVID-19. Acta Psychiatr Scand. 2021;144:82–91.
2. Chen S, Fernandez-Egea E, Jones PB, et al. Mental disorders and COVID-19-related mortality: results from 49,089 COVID-19 inpatients. Mol Psychiatry. 2021;1–3. doi:10.1038/s41380-021-01393-7.
3. Vai B, Mazza MG, Delli Colli C, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021; 8:797–812.
4. Hoertel N, Sánchez-Rico M, Herrera-Morueco JJ, et al. Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: results from 49,089 COVID-19 inpatients. Mol Psychiatry. 2021;1–3.
6. Sánchez-Rico M, Limosín F, Hoertel N. Is a diagnosis of schizophrenia spectrum disorder associated with increased mortality in patients with COVID-19? Am J Psychiatry. 2022;179:71–73.

7. Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol. 2006;47:330–342.

8. Köhler CA, Freitas TH, Stubbs B, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018;55:4195–4206. doi:10.1007/s12035-017-0632-1.

9. Hoertel N, Sánchez-Rico M, Vernet R, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199–5212.

10. Diez-Quevedo C, Iglesias-González M, Giralt-López M, et al. Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients. Acta Psychiatr Scand. 2021;143:526–534.

11. Peters MD, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13:141–146.

12. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292–2300.

13. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51.

14. Calusci M, Marcce R, Lukka L, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021. doi: 10.1111/bcp.15126.

15. Selhel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open forum. Infect Dis. 2021;8:ofab050.

16. Oskotsky T, Maric I, Tang A, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4:e213090.

17. Clleland CL, Ramiah K, Steinberg L, et al. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open. 2021;8;e6.

18. Németh ZK, Szobi A, Vitráj J, et al. Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study. Ideggyogy Sz. 2021;74:389–396.

19. Hoertel N, Sánchez-Rico M, Gougeon C, et al. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry. 2021;26:7098–7099.

20. Bonnet U, Jhubar Tripal P, Reichel M, et al. Functional inhibitors of acid sphingomyelinase (FIASMA): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2020;10:699–20.

21. Bonnet U, Hoertel N, Gubins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. 2021;1:1–8. doi: 10.1038/s41386-021-01309-5.

22. Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Netw Open. 2021;4:e2136510.

23. Le Corre P, Loas G. Repurposing functional inhibitors of acid sphingomyelinase (FIASMA): an opportunity against SARS-CoV-2 infection? J Clin Pharm Ther. 2021;46:1213–1219.

24. Bonnet U, Bingmann D, Wiltfang J, et al. Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence. Drugs. 2021;81:2081–2089.

25. Facente SN, Reiersen AM, Lenze EJ, et al. Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence. Drugs. 2021;81:2081–2089.

26. Zimniak M, Kirschner L, Hilpert H, et al. The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep. 2021;11:5890.

27. Hori H, Yoshimura R, Ueda N, et al. A case with occurring adverse effects in COVID-19 Spanish inpatients. Mol Psychiatry. 2021;143:526–534.

28. Schloer S, Brunotte L, Gortzko J, et al. Targeting the endolysosomal host-virus interaction to prevent SARS-CoV-2 infection by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020;9:2245–2255.

29. Bonnet U, Zheng S, Mecate-Zambrano A, et al. Combination therapy with fluoxetine and the nuclease analog GS-441524 exerts synergistic antiviral effects against different SARS-CoV-2 variants in vitro. Pharmaceuticals. 2021;13:400.

30. Kornhuber J, Trujillo Tripal P, Reichel M, et al. Functional inhibitors of acid sphingomyelinase (FIASMA): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2020;10:699–20.

31. Kornhuber J, Hoertel N, Gubins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. 2021;1:1–8. doi: 10.1038/s41386-021-01309-5.

32. Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Netw Open. 2021;4:e2136510.

33. Le Corre P, Loas G. Repurposing functional inhibitors of acid sphingomyelinase (FIASMA): an opportunity against SARS-CoV-2 infection? J Clin Pharm Ther. 2021;46:1213–1219.

34. Kornhuber J, Muchlacher M, Trapp S, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6:e23852.

35. Khodadoust MM. Inferring a causal relationship between ceramide levels and COVID-19 respiratory distress. Sci Rep. 2021;11:20866.

36. Torretta E, Garziano M, Poliseno M, et al. Severity of COVID-19 patients predicted by serum sphingolipids signature. Int J Mol Sci. 2021;22:10198.

37. Orbán I, Vassallo I, Morató J, et al. Metabolic and COVID-19 respiratory distress. Sci Transl Med. 2019;11:eau5266.

38. Kornhuber J, Troppel A, Reichel M, et al. Functional inhibitors of acid sphingomyelinase (FIASMA): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2020;10:699–20.

39. Kornhuber J, Hoertel N, Gubins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. 2021;1:1–8. doi: 10.1038/s41386-021-01309-5.

40. Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Netw Open. 2021;4:e2136510.

41. Le Corre P, Loas G. Repurposing functional inhibitors of acid sphingomyelinase (FIASMA): an opportunity against SARS-CoV-2 infection? J Clin Pharm Ther. 2021;46:1213–1219.

42. Kornhuber J, Muchlacher M, Trapp S, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6:e23852.

43. Khodadoust MM. Inferring a causal relationship between ceramide levels and COVID-19 respiratory distress. Sci Rep. 2021;11:20866.

44. Torretta E, Garziano M, Poliseno M, et al. Severity of COVID-19 patients predicted by serum sphingolipids signature. Int J Mol Sci. 2021;22:10198.

45. Orbán I, Vassallo I, Morató J, et al. Metabolic and COVID-19 respiratory distress. Sci Transl Med. 2019;11:eau5266.

46. Ondícova K, Tillinger A, Pecenák J, et al. The role of the vagus nerve in inflammation and sepsis. J Neuroinflammation. 2021;18:CD006114.